The Pharma Summit

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Home

February 11th 2010
  • Renaissance Chancery Court, London

Technology, reform and innovation are driving significant changes in how healthcare is delivered. The pharma industry will play a crucial role in shaping this, but will need to innovate to stay ahead.

Now in its 16th year, The Pharma Summit is the strategic forum to understand how firms can take advantage of these developments and drive future competitive advantage. Taking place in London on February 11th 2010, the event will bring together 150 senior executives from across pharma including some of the industry's most influential names.
 

GET INSIGHT FROM TWO OF THE INDUSTRY'S LEADING CHIEF EXECUTIVES: hear their unique visions for the future of pharma
DISCOVER HOW BUSINESS MODELS ARE CHANGING to reflect the innovation in healthcare delivery
LEARN ABOUT THE EVOLVING CUSTOMER from other industries and how patients are now driving changes
DISCOVER NEW HEALTHCARE TECHNOLOGIES: understand the challenges and opportunities that it offers pharma
HEAR THE ECONOMIST INTELLIGENCE UNIT'S LATEST FORECAST: for the markets that will lead the industry's growth in 2010
FIND OUT ABOUT THE FUTURE OF INNOVATION IN PHARMA and how biohackers can change the way the industry innovates

 

Superb speakers include:

- David Brennan, Chief Executive Officer, AstraZeneca
- Werner Cautreels, Chief Executive Officer, Solvay Pharmaceuticals
- Ornella Barra, Chief Executive, Pharmaceutical Wholesale Division, Alliance Boots
- Roch Doliveux, Chief Executive Officer and Chairman of the Executive Committee, UCB
- Jon Achenbaum, Senior Vice-president Global Strategic Marketing, Bayer HealthCare Diabetes Care
- Ulf Wiinberg, President and Chief Executive Officer, H. Lundbeck
- Jeff George, Chief Executive Officer, Sandoz
- Ranjit Shahani, Country President, Novartis India
- Paul Stoffels, Global Head, Research & Development, Johnson & Johnson Pharmaceuticals
- Patrick Flochel, Partner, EMEIA Life Sciences Leader, Ernst & Young


Pharma Summit Bottom Banner

   

 

Programme

09.00

CHAIRMAN'S WELCOME

Natasha Loder, Science and Technology Correspondent, The Economist
09:10

VISIONS OF THE FUTURE OF PHARMA - I:

David Brennan, Chief Executive Officer, AstraZeneca
09:40

REVOLUTION IN HEALTHCARE: Building a role in a changing system
Patients are taking ever more control of their own health, and new technology means healthcare is being delivered in new, innovative ways.  Pharma companies need to anticipate the changes and adapt.

• Overview: a shifting healthcare landscape - a journey through regulatory, technological and social forces driving change in the next three years
• What are pharma's most exciting, promising responses so far to changes in healthcare delivery?
• What kind of leadership is needed in the industry to build pharma's role in the future healthcare system?

Ornella Barra, Chief Executive, Pharmaceutical Wholesale Division, Alliance Boots
Jeff George, Chief Executive Officer, Sandoz
Iain Scott, Senior Editor, Economist Intelligence Unit
Ulf Wiinberg, President & Chief Executive Officer, H. Lundbeck
10.40 REFRESHMENT BREAK
11.10

PATIENTS DRIVING HEALTHCARE INNOVATION: How patients are changing the system and society around them by taking control of their health
Society is providing more non-medical means for people to stay healthy, and patients are demanding more choice when it comes to their wellbeing.  This panel will consider some exciting, innovative responses. 

• How should pharma respond to increasing patient empowerment?
• How can pharma companies understand their new customers and build business models around a changing moment of truth?
• What can pharma learn from other industries about consumer understanding and online delivery models?  

Jon Achenbaum, Senior Vice-president, Global Strategic Marketing and Head of Latin America Commercial Operations, Bayer Healthcare Diabetes Care
Roch Doliveux, Chief Executive Officer and Chairman of the Executive Committee, UCB
Janice Haigh, Senior Director, Pricing & Market Access - Europe, Astellas Pharma Europe
12.10

THE FUTURE OF HEALTHCARE TECHNOLOGY: embracing the challenge to ‘business as usual’
Healthcare technology will lead some of the biggest changes to business and society this century. It offers pharma dramatic new sources of growth, and some of the biggest challenges it is yet to face.

• Visions of the long-term future of healthcare technology
• Preparing for shifts: building an agile culture to adapt to technology-driven changes
• Squeezing opportunities from disruption: using technology to drive innovative new business models

Patrick Flochel, Partner, EMEIA Life Sciences Leader, Ernst & Young
Hans Hofstraat, Vice-president, Healthcare Strategic Partnerships, Philips Research
Michael Reilly, Director, Orange Healthcare UK
David Gillen, Vice-president Primary Care Business Unit, Pfizer
13:10 LUNCH
14:30

EMERGING MARKETS: different rules and fresh thinking in emerging market healthcare
The Economist intelligence unit will give an overview of growth prospects in emerging markets, and a panel will discuss the most intelligent strategies to find success in particular countries.

Discussion
• How can pharma leaders use the cultural, regulatory and infrastructural differences in emerging markets to drive innovation?
• How can healthcare be made affordable in the developing world?

Robert Ward, Director, Global Forecasting; Deputy Director, Country Analysis, Economist Intelligence Unit
Mazen Darwazah, Vice-chairman, Hikma Pharmaceuticals
Jostein Davidsen, General Director, Nycomed Russia-CIS & Senior Vice-president, Nycomed Group
Ranjit Shahani, Country President, Novartis India
Bright Simons, Co-ordinator, mPedigree
15.30

VISIONS OF THE FUTURE OF PHARMA - II:

Paul Stoffels, Global Head, Research & Development, Johnson & Johnson Pharmaceuticals
16:00 SUMMARY AND CLOSE OF CONFERENCE

Speakers

David Brennan David Brennan
Chief Executive Officer, AstraZeneca
David will propose a vision for the future of the industry and his view on how business leaders should be preparing for it.		 Roch Doliveux
Chief Executive Officer and Chairman of the Executive Committee, UCB
Roch will talk about UCB’s exciting patient-driven innovations and how the company is benefiting from them.
Paul Stoffels Paul Stoffels
Global Head, Research & Development,
Johnson & Johnson Pharmaceuticals
Paul's vision for the future of pharma will challenge delegates to consider how they can ready their companies.		 Ulf Wiinberg
President & Chief Executive Officer,
H. Lundbeck
Ulf will talk about how he plans to respond to rapid change.
Jeff George
Chief Executive Officer, Sandoz
Jeff will bring insights from his experience leading this major, pioneering generics company.		 Ranjit Shanhani
Country President,
Novartis India
Ranjit will talk about the importance of innovation to make the most of prospects in emerging markets, relating to his experience leading Novartis in India
Janice Haigh
Senior Director, Pricing & Market Access - Europe, Astellas Pharma Europe
Janice is ready to redefine the way the pharmaceutical industry markets itself, in line with the changing role of patients, physicians and other stakeholders in the European healthcare system.
Jon Achenbaum
Senior Vice-president, Global Strategic Marketing,
Bayer HealthCare
Diabetes Care
Jon will talk about Didget – the Bayer gadget that allows children to manage their diabetes using their Nintendo DS.
Mazen Darwazah
Vice-chairman,
Hikma Pharmaceuticals
Mazen will share insights from Hikma’s leading expertise in the Middle East.		 Jostein Davidsen
General Director, Nycomed Russia-CIS & Senior Vice-president,
Nycomed Group
Jostein will talk about why Nycomed is investing in Russia-CIS and what strategies work best in these markets.
Ornella Barra
Chief Executive, Pharmaceutical Wholesale Division, Alliance Boots
Ornella will share the wholesalers’ perspective on changes taking place in healthcare.		 Hans Hofstraat
Vice-president, Healthcare Strategic Partnerships
Philips Research
Hans will talk about the healthcare technology that Philips is developing, and what technology like this means for the future of healthcare.
Jim Haseloff
Research Scientist and Lecturer, University of Cambridge
Jim is a pioneering biologist who takes part in the annual Internationally Genetically Engineered Machine competition, a jamboree that is changing science, where undergraduates have engineered bacteria that can do the work of a failed kidney or show quickly whether water is safe to drink.		 Bright Simons
Co-ordinator, mPedigree
Bright was disturbed by the problem of counterfeit drugs in his home country, Ghana, so he invented a system that allows patients to verify the validity of medicines using their mobile phones.  mPedigree is an inspiring example of how innovation can overcome challenges in emerging markets.
Geoffrey Carr
Science Editor,
The Economist
Geoffrey will bring The Economist’s angle on the outlook for synthetic biology. 		Patrick Flochel
Partner, EMEIA Life Sciences Leader, Ernst & Young
Patrick will share his expertise in the technology with potential to revolutise pharma.
Natasha Loder Natasha Loder
Science and Technology Correspondent,
The Economist
Natasha will bring The Economist’s ideas and opinions to the day’s discussions.		 Robert Ward

 Robert Ward
Director, Global forecasting; Deputy Director, Country Analysis, Economist Intelligence Unit
Robert is our in-house oracle.  He will run through the EIU’s forecast for the markets that promise the best growth prospects for pharma in the next 5 years.
Michael Reilly
Director, Orange Healthcare UK
Michael will share some insights into the future of mobile health, based on the work that Orange is doing in this area.		 David Gillen David Gillen
Vice-president Primary Care Business Unit, Pfizer
David will give the perspective of an industry leader on the possibilities that new healthcare technology opens up for pharma.
Iain Scott
Senior Editor, Economist Intelligence Unit
Iain will share his expertise in the forces that are shaping the healthcare industry, and talk about how the most exciting changes are likely to impact pharma.		    

Who attends?

The Pharma Summit 2010 will bring together over 150 senior industry executives. Representatives already registered to attend come from across 14 countries and major organisations that include:

  • Access to Medicine Index
  • Alliance Boots
  • Association of the British Pharmaceutical Industry
  • Astellas Pharma Europe
  • AstraZeneca
  • Bank of America Merill Lynch
  • Baxter Healthcare
  • Bayer HealthCare Diabetes Care
  • Biotica Technology
  • Calent Pharma Solutions
  • Chugai Pharma Europe
  • ClinTec International
  • Cilag
  • Deutsche Bank
  • Dr Reddy's Laboratories
  • Economist Intelligence Unit
  • Ernst & Young
  • Fulcrum Pharma
  • GlaxoSmithKline
  • Grupo Leti
  • H. Lundbeck
  • Hikma Pharmaceuticals
  • Hobson Prior
  • IBM
  • Ipsen
  • Janssen-Cilag Russia
  • Johnson & Johnson
  • Kloeckner Pentaplast
  • Leiden Bio Science Park
  • Mediq
  • Moelis & Co
  • mPedigree
  • Novartis
  • Novo Nordisk
  • Nycomed Group
  • Oracle
  • Orange Healthcare UK
  • Pfizer
  • Philips Research
  • Phoenix Medical Supplies
  • Quintiles
  • RAND Europe
  • Sandoz Pharma
  • Santaris Pharma
  • Solvay Pharmaceuticals
  • The Economist
  • UCB Group
  • UK National Screening Committee
  • United Drug
  • University of Cambridge
  • Wyeth Pharmaceuticals
  • ZaiCom International
  • Zambon

"The Economist event presented a diverse range of arguments and viewpoints that were genuinely stimulating, the sum of which suggested to me that a Golden Age of conferencing could be being ushered in by the economic Dark Age."
Editor, Pharmaceutical Executive Europe, February 24th 2009

“Inspiring!”
Public Affairs & Policy Director, Pfizer

“Top level view of the Pharma sector”
NBD Director Emerging Markets, Solvay Pharma

“Stimulating”
Senior Director, Almirall

“Very thought provoking content”
Director, Life Sciences, Cyril Sweett

Partners

 



Pharma Exec Europe logo 

 

 

Pharma Marketing News

 

 

Pharma Ventures

 

  Scrip Logo

 

Companies in the pharma sector are scrutinising their business models and taking drastic action to survive the economic downturn. Sign up for a FREE 5-day trial today and let Scrip's team of journalists and analysts provide you with the pharmaceutical business intelligence you need to build a robust business strategy and stay ahead. Start your free trial today at http://www.scripnews.com/freeTrial
 
Scrip comprises Scrip World Pharmaceutical News, a weekly print newsletter and Scripnews.com, an online global pharma news and analysis service. Scrip’s authoritative, unbiased coverage includes policy & regulation, business, R&D, generics, drug delivery and clinical trials. E: scripnews@informa.com

Register

  FEES

Excl. VAT VAT Price inc. VAT
Standard Delegate Rate   £995.00 £174.13 £1,169.13
Group Rate (rate per person when   
three or more delegates register)		 £895.00 £156.63 £1,029.25


Please note:
* Your payment must be received prior to attendance.
** Discounts cannot be combined
*** Your registration fee includes refreshments, lunches and your conference materials.

  BOOKING OPTIONS

1. Online  

Please note you will be directed to an external site to complete your booking.

2. By Post or Fax

Please download the registration form and return by FAX to '+44 (0)207 576 8472' or by POST to 'Customer Sevices, Economist Conferences, 26 Red Lion Square, London WC1R 4HQ, United Kingdom'

3. By Phone

Please call customer services on +44 (0)207 576 8118

Enquiries

For any enquires, please email our customer service team.



An Economist Group business. All rights reserved.